Successful anti-cancer drug targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets. - Anatoly L. Mayburd; Inna Golovchikova; James L. Mulshine (Bioinform., 2008)

Knowledge-based compact disease models identify new molecular players contributing to early-stage Alzheimer's disease. - Anatoly L. Mayburd; Ancha V. Baranova (BMC Syst. Biol., 2013)